Article Listing - Auriga signs manufacturing deal with Mikart
PFIZER PLANS NEW UNIT IN USA
10 February 1992
US pharmaceutical concern Pfizer is setting up a new unit at its Groton plant in the USA.The company has...
END OF FRENCH BLOC ON NEW DRUG INTROS
3 February 1992
The French government has agreed to renew the commission which gives advice to the Health Minister on drug-price fixing for...
RU's DIMETROSE FOR CYCLIC MASTALGIA
3 February 1992
A multicenter study investigating the applicability and safety of Roussel Uclaf's Dimetrose (gestrinone) as a treatment for women with cyclical...
PROTEUS INTERNATIONAL "PROCEEDING TO PLAN"
3 February 1992
The six months to September 1991 saw continuing developments for UK computer-aided molecular modelling and drug design company Proteus International....
WYETH AYERST/ TLC FLU VACCINE DEAL
3 February 1992
Wyeth-Ayerst Laboratories, a division of American Home Products, has entered into an agreement with The Liposome Company concerning the development...
ROBERTS' SOMAGARD APPROVED IN EIRE
3 February 1992
Roberts Pharmaceutical Corporation has been granted marketing approval by the Republic of Ireland's regulatory authorities for its prostate cancer treatment...
STOCK MARKET COMMENTARY: TOKYO
3 February 1992
TOKYO: closed with a 0.4% gain at 21,007.11 yen after a volatile trading week dominated by index and futures- linked...
STOCK MARKET COMMENTARY: EUROPE
3 February 1992
EUROPE: saw ups and downs on the reporting week, with Belgium, Germany and Switzerland the strongest stock markets. FRANKFURT saw...
DU PONT'S JOHN KROL
3 February 1992
- John Krol has been named as a vice chairman and director of Du Pont Co.
APPOINTMENTS AT BRISTOL-MYERS SQUIBB
3 February 1992
- At Bristol-Myers Squibb Co, Wesley Thompson has been appointed president of the Bristol-Myers Squibb Consumer Products International division....
- Is failure to adopt business process management putting the pharma industry at risk?
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- New Zealand declines Alexion's funding application for Solaris
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Elan makes "transformational" acquisitions and a divestment
